This article is more than 5 years old. Information may no longer be current.

VIDEO: Takeda executive highlights research efforts in lung cancer, myeloma, myelodysplastic syndrome

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Stephen Noga, MD, PhD, vice president of U.S. medical affairs for Takeda Oncology, spoke with HemOnc Today at ASCO Annual Meeting about several trials underway to assess agents in the company’s oncology pipeline.

Noga discussed the ALTA trial, the results from which prompted FDA to grant accelerated approval to brigatinib (Alunbrig, Takeda Oncology) for the treatment of patients with ALK-positive metastatic non-small cell lung cancer who progressed on or were intolerant of crizotinib (Xalkori; Pfizer, EMD Serono).

Takeda now is assessing brigatinib as frontline treatment for patients with NSCLC.

Noga spoke about the TOURMALINE clinical trials program, in which researchers are assessing ixazomib (Ninlaro, Takeda) in the first-line and maintenance settings for patients with multiple myeloma.

He also highlighted the phase 3 PANTHER trial, designed to assess pevonedistat (Takeda) plus azacytidine (Vidaza, Celgene) for treatment of myelodysplastic syndrome.